Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

[Clinical significance of high sensitivity C-reactive protein for evaluating the efficacy of etanercept in active ankylosing spondylitis].

Zhang J, Huang F, Zhang J, Deng X, Zhang Y.

Zhonghua Yi Xue Za Zhi. 2014 Jan 21;94(3):204-7. Chinese.

PMID:
24731464
[PubMed - indexed for MEDLINE]
2.

Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.

van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS.

Rheumatology (Oxford). 2012 Oct;51(10):1894-905. Epub 2012 Jul 6.

PMID:
22772319
[PubMed - indexed for MEDLINE]
Free Article
3.

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.

Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.

Ann Rheum Dis. 2010 Jun;69(6):1065-71. doi: 10.1136/ard.2009.111187. Epub 2009 Sep 9.

PMID:
19740906
[PubMed - indexed for MEDLINE]
4.

Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis.

Chou CT, Tsai CY, Liang TH, Chang TM, Lai CH, Wei CC, Chen KH, Lin SC, Yu CL, Liou LB, Luo SF, Lee CS, Hsue YT, Huang CM, Chen JH, Lai NS, Cheng HH, Cheng TT, Lai HM, Tsai WC, Yen JH, Lu LY, Chang CP.

Mod Rheumatol. 2010 Dec;20(6):580-7. doi: 10.1007/s10165-010-0334-2. Epub 2010 Aug 4.

PMID:
20683633
[PubMed - indexed for MEDLINE]
5.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

PMID:
19877087
[PubMed - indexed for MEDLINE]
Free Article
6.

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2003 Jun;48(6):1667-75.

PMID:
12794835
[PubMed - indexed for MEDLINE]
Free Article
7.

Etanercept in the longterm treatment of patients with ankylosing spondylitis.

Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, van der Heijde D, van der Linden S, Wajdula J.

J Rheumatol. 2009 Jun;36(6):1256-64. doi: 10.3899/jrheum.081033. Epub 2009 May 1. Erratum in: J Rheumatol. 2010 Oct;37(10):2198.

PMID:
19411393
[PubMed - indexed for MEDLINE]
8.

[Clinical study of etanercept for treating ankylosing spondylitis].

Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(8):1349-51. Chinese.

PMID:
18753057
[PubMed - indexed for MEDLINE]
Free Article
9.

[Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].

Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.

Zhonghua Yi Xue Za Zhi. 2006 Sep 19;86(35):2451-4. Chinese.

PMID:
17156669
[PubMed - indexed for MEDLINE]
10.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

PMID:
21689401
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.

Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.

Ann Rheum Dis. 2004 Jun;63(6):665-70. Epub 2004 Mar 22.

PMID:
15037444
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

PMID:
17651658
[PubMed - indexed for MEDLINE]
Free Article
13.

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.

Ann Rheum Dis. 2004 Dec;63(12):1594-600. Epub 2004 Sep 2.

PMID:
15345498
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.

Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J.

Arthritis Res Ther. 2013;15(3):R67.

PMID:
23786760
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China.

Xu M, Lin Z, Deng X, Li L, Wei Y, Liao Z, Li Q, Wei Q, Hu Z, Zhang Y, Lin Q, Huang J, Li T, Pan Y, Wu Y, Jin O, Yu B, Gu J.

Rheumatology (Oxford). 2011 Aug;50(8):1466-72. doi: 10.1093/rheumatology/ker087. Epub 2011 Mar 26.

PMID:
21441550
[PubMed - indexed for MEDLINE]
Free Article
16.

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.

van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R; Assessment of SpondyloArthritis international Society (ASAS).

Ann Rheum Dis. 2009 Dec;68(12):1811-8. doi: 10.1136/ard.2008.100826. Epub 2008 Dec 5.

PMID:
19060001
[PubMed - indexed for MEDLINE]
17.

Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.

Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kaufmann C, Rødevand E, Mikkelsen K, Kalstad S, Kvien TK.

Rheumatology (Oxford). 2012 Aug;51(8):1479-83. doi: 10.1093/rheumatology/kes057. Epub 2012 Apr 11.

PMID:
22499062
[PubMed - indexed for MEDLINE]
Free Article
18.

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group.

Arthritis Rheum. 2003 Nov;48(11):3230-6.

PMID:
14613288
[PubMed - indexed for MEDLINE]
Free Article
19.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.

Arthritis Rheum. 2005 Dec 15;53(6):856-63.

PMID:
16342093
[PubMed - indexed for MEDLINE]
Free Article
20.

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).

Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, Thabut G, Leblanc V, Logeart I.

Ann Rheum Dis. 2011 May;70(5):799-804. doi: 10.1136/ard.2010.139261. Epub 2011 Feb 13. Erratum in: Ann Rheum Dis. 2011 Jul;70(7):1349.

PMID:
21317434
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk